CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Phase 1
60
about 23 years
12–75
2 sites in TX
Why this study is shown
What this study is about
This trial is testing a new treatment called CD30 CAR T cells for people with lymphoma that has returned after other treatments. The goal is to see if these modified T cells can better kill cancer cells and improve outcomes.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take CAR T Cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cell therapy (Engineered T-cells that target specific cancer antigens)
Primary: Number of Patients with Dose-Limiting Toxicities (DLT)
Secondary: Overall Response Rate
Oncology